HUAREN PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.6 CNY | -0.28% |
|
-3.23% | -14.69% |
| 04-25 | Huaren Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2023 | CI |
| 04-24 | Huaren Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 3,795 | 4,989 | 5,592 | 5,675 | 5,013 | 4,989 |
| Enterprise Value (EV) 1 | 3,895 | 4,809 | 5,900 | 7,098 | 6,462 | 6,321 |
| P/E ratio | 107 x | 117 x | 59.1 x | 43.6 x | 27.7 x | 26.5 x |
| Yield | 0.93% | 0.24% | 0.32% | 0.38% | 0.5% | 0.5% |
| Capitalization / Revenue | 2.74 x | 3.41 x | 3.46 x | 3.64 x | 3.1 x | 3.05 x |
| EV / Revenue | 2.81 x | 3.29 x | 3.65 x | 4.55 x | 3.99 x | 3.86 x |
| EV / EBITDA | 21 x | 23.3 x | 26.2 x | 19.8 x | 17.3 x | 13.5 x |
| EV / FCF | 28.4 x | 15.3 x | -186 x | -11.2 x | 48.8 x | 21.6 x |
| FCF Yield | 3.52% | 6.53% | -0.54% | -8.93% | 2.05% | 4.64% |
| Price to Book | 1.74 x | 2.29 x | 2.48 x | 2.39 x | 1.98 x | 1.85 x |
| Nbr of stocks (in thousands) | 1,182,213 | 1,182,213 | 1,182,213 | 1,182,213 | 1,182,213 | 1,182,213 |
| Reference price 2 | 3.210 | 4.220 | 4.730 | 4.800 | 4.240 | 4.220 |
| Announcement Date | 4/19/19 | 3/30/20 | 3/19/21 | 3/30/22 | 3/24/23 | 4/24/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 1,384 | 1,462 | 1,616 | 1,561 | 1,619 | 1,636 |
| EBITDA 1 | 185.4 | 206.8 | 225.2 | 358.1 | 373.8 | 468.6 |
| EBIT 1 | 71.81 | 96.57 | 114.5 | 226.6 | 226.6 | 344.8 |
| Operating Margin | 5.19% | 6.61% | 7.08% | 14.52% | 13.99% | 21.08% |
| Earnings before Tax (EBT) 1 | 43.56 | 67.41 | 111.6 | 150.3 | 205.9 | 230.5 |
| Net income 1 | 38.79 | 42.07 | 94.62 | 130.4 | 180.8 | 188.1 |
| Net margin | 2.8% | 2.88% | 5.85% | 8.35% | 11.16% | 11.49% |
| EPS 2 | 0.0300 | 0.0360 | 0.0800 | 0.1100 | 0.1530 | 0.1590 |
| Free Cash Flow 1 | 137 | 314.3 | -31.71 | -634.2 | 132.5 | 293.2 |
| FCF margin | 9.9% | 21.5% | -1.96% | -40.63% | 8.18% | 17.92% |
| FCF Conversion (EBITDA) | 73.91% | 151.95% | - | - | 35.44% | 62.57% |
| FCF Conversion (Net income) | 353.11% | 747.05% | - | - | 73.26% | 155.89% |
| Dividend per Share 2 | 0.0300 | 0.0100 | 0.0150 | 0.0180 | 0.0210 | 0.0210 |
| Announcement Date | 4/19/19 | 3/30/20 | 3/19/21 | 3/30/22 | 3/24/23 | 4/24/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 99.8 | - | 308 | 1,423 | 1,450 | 1,332 |
| Net Cash position 1 | - | 180 | - | - | - | - |
| Leverage (Debt/EBITDA) | 0.5382 x | - | 1.367 x | 3.974 x | 3.879 x | 2.842 x |
| Free Cash Flow 1 | 137 | 314 | -31.7 | -634 | 132 | 293 |
| ROE (net income / shareholders' equity) | 1.97% | 2.01% | 4.23% | 5.62% | 7.19% | 7.21% |
| ROA (Net income/ Total Assets) | 1.49% | 2.06% | 2.34% | 3.13% | 2.62% | 4.17% |
| Assets 1 | 2,609 | 2,042 | 4,051 | 4,169 | 6,898 | 4,506 |
| Book Value Per Share 2 | 1.840 | 1.840 | 1.910 | 2.010 | 2.140 | 2.280 |
| Cash Flow per Share 2 | 0.5200 | 0.3200 | 0.1900 | 0.3500 | 0.1900 | 0.2000 |
| Capex 1 | 45.5 | 32 | 58 | 27.9 | 42.3 | 45.9 |
| Capex / Sales | 3.29% | 2.19% | 3.59% | 1.78% | 2.61% | 2.8% |
| Announcement Date | 4/19/19 | 3/30/20 | 3/19/21 | 3/30/22 | 3/24/23 | 4/24/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -14.69% | 588M | |
| +22.35% | 44.12B | |
| +22.22% | 22.61B | |
| +18.00% | 15.11B | |
| +15.73% | 13.61B | |
| +57.91% | 13.34B | |
| -8.98% | 6.94B | |
| -0.05% | 6.79B | |
| +15.65% | 5.75B | |
| -8.87% | 5.73B |
- Stock Market
- Equities
- 300110 Stock
- Financials Huaren Pharmaceutical Co., Ltd.